In the trial, Dupixent ® (dupilumab) ... Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron ...

Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial. ... Regeneron, and ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Trial Shows Dupilumab Reduces Itch, Disease Activity, Steroid Use in Bullous Pemphigoid. ... Both Caux and Werth reported financial relationships with Regeneron Pharmaceuticals.

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has ...

Dupilumab (Dupixent; Regeneron, ... Children without an allergic phenotype in the dupilumab group (n = 49) in the VOYAGE trial had a rate of 0.429 compared with 0.749 in children in the placebo ...

In addition, treatment with dupilumab resulted in a 15.86-point reduction in urticaria activity (itch and hive) severity from baseline versus an 11.21-point reduction with placebo (-4.7 difference ...